170 related articles for article (PubMed ID: 24116674)
1. Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design.
Barakat KH; Law J; Prunotto A; Magee WC; Evans DH; Tyrrell DL; Tuszynski J; Houghton M
J Chem Inf Model; 2013 Nov; 53(11):3031-43. PubMed ID: 24116674
[TBL] [Abstract][Full Text] [Related]
2. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.
Sofia MJ; Chang W; Furman PA; Mosley RT; Ross BS
J Med Chem; 2012 Mar; 55(6):2481-531. PubMed ID: 22185586
[No Abstract] [Full Text] [Related]
4. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.
Schoenfeld RC; Bourdet DL; Brameld KA; Chin E; de Vicente J; Fung A; Harris SF; Lee EK; Le Pogam S; Leveque V; Li J; Lui AS; Najera I; Rajyaguru S; Sangi M; Steiner S; Talamas FX; Taygerly JP; Zhao J
J Med Chem; 2013 Oct; 56(20):8163-82. PubMed ID: 24069953
[TBL] [Abstract][Full Text] [Related]
6. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
Brown JA; Thorpe IF
Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.
Elfiky AA; Elshemey WM; Gawad WA; Desoky OS
Protein J; 2013 Jan; 32(1):75-80. PubMed ID: 23322006
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of L- and D-phenylalanine derived rhodanines with novel C5-arylidenes as inhibitors of HCV NS5B polymerase.
Patel BA; Krishnan R; Khadtare N; Gurukumar KR; Basu A; Arora P; Bhatt A; Patel MR; Dana D; Kumar S; Kaushik-Basu N; Talele TT
Bioorg Med Chem; 2013 Jun; 21(11):3262-71. PubMed ID: 23598249
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors.
Biswal BK; Cherney MM; Wang M; Chan L; Yannopoulos CG; Bilimoria D; Nicolas O; Bedard J; James MN
J Biol Chem; 2005 May; 280(18):18202-10. PubMed ID: 15746101
[TBL] [Abstract][Full Text] [Related]
10. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
Manjula S; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation.
Ryu K; Kim ND; Choi SI; Han CK; Yoon JH; No KT; Kim KH; Seong BL
Bioorg Med Chem; 2009 Apr; 17(8):2975-82. PubMed ID: 19332375
[TBL] [Abstract][Full Text] [Related]
12. 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.
Nyanguile O; Pauwels F; Van den Broeck W; Boutton CW; Quirynen L; Ivens T; van der Helm L; Vandercruyssen G; Mostmans W; Delouvroy F; Dehertogh P; Cummings MD; Bonfanti JF; Simmen KA; Raboisson P
Antimicrob Agents Chemother; 2008 Dec; 52(12):4420-31. PubMed ID: 18852280
[TBL] [Abstract][Full Text] [Related]
13. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into NS5B protein of novel equine hepaciviruses and pegiviruses complexed with polymerase inhibitors.
de Albuquerque PPLF; Santos LHS; Antunes D; Caffarena ER; Figueiredo AS
Virus Res; 2020 Mar; 278():197867. PubMed ID: 31972246
[TBL] [Abstract][Full Text] [Related]
15. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
[TBL] [Abstract][Full Text] [Related]
16. New NS5B polymerase inhibitors for hepatitis C.
Legrand-Abravanel F; Nicot F; Izopet J
Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614
[TBL] [Abstract][Full Text] [Related]
17. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
[TBL] [Abstract][Full Text] [Related]
18. Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy.
Wu JZ; Hong Z
Curr Drug Targets Infect Disord; 2003 Sep; 3(3):207-19. PubMed ID: 14529354
[TBL] [Abstract][Full Text] [Related]
19. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
Beaulieu PL
Curr Opin Investig Drugs; 2007 Aug; 8(8):614-34. PubMed ID: 17668364
[TBL] [Abstract][Full Text] [Related]
20. Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid.
Stansfield I; Avolio S; Colarusso S; Gennari N; Narjes F; Pacini B; Ponzi S; Harper S
Bioorg Med Chem Lett; 2004 Oct; 14(20):5085-8. PubMed ID: 15380204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
